JP2002544233A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002544233A5 JP2002544233A5 JP2000617903A JP2000617903A JP2002544233A5 JP 2002544233 A5 JP2002544233 A5 JP 2002544233A5 JP 2000617903 A JP2000617903 A JP 2000617903A JP 2000617903 A JP2000617903 A JP 2000617903A JP 2002544233 A5 JP2002544233 A5 JP 2002544233A5
- Authority
- JP
- Japan
- Prior art keywords
- glycosaminoglycan
- pharmaceutical composition
- composition according
- molecular weight
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002683 Glycosaminoglycan Polymers 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 206010039966 Senile dementia Diseases 0.000 description 3
- 230000006931 brain damage Effects 0.000 description 2
- 231100000874 brain damage Toxicity 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 101100424823 Arabidopsis thaliana TDT gene Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT99A001066 | 1999-05-14 | ||
| IT1999MI001066A IT1312107B1 (it) | 1999-05-14 | 1999-05-14 | Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile |
| PCT/EP2000/004311 WO2000069444A1 (en) | 1999-05-14 | 2000-05-12 | Glycosaminoglycans having an average molecular weight equal to 2400 d suitable for the treatment of senile dementia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002544233A JP2002544233A (ja) | 2002-12-24 |
| JP2002544233A5 true JP2002544233A5 (enExample) | 2007-07-12 |
Family
ID=11382970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000617903A Pending JP2002544233A (ja) | 1999-05-14 | 2000-05-12 | 老人性痴呆症の治療に適した平均分子量が２，４００ｄに等しいグリコサミノグリカン |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6979680B1 (enExample) |
| EP (1) | EP1181024B1 (enExample) |
| JP (1) | JP2002544233A (enExample) |
| KR (1) | KR100711142B1 (enExample) |
| CN (1) | CN1178667C (enExample) |
| AT (1) | ATE288761T1 (enExample) |
| AU (1) | AU764743C (enExample) |
| CA (1) | CA2373975A1 (enExample) |
| CZ (1) | CZ20014092A3 (enExample) |
| DE (1) | DE60018061T2 (enExample) |
| DK (1) | DK1181024T3 (enExample) |
| ES (1) | ES2237425T3 (enExample) |
| HK (1) | HK1039903B (enExample) |
| HU (1) | HUP0201100A3 (enExample) |
| IL (1) | IL146458A0 (enExample) |
| IT (1) | IT1312107B1 (enExample) |
| NO (1) | NO328902B1 (enExample) |
| PL (1) | PL198016B1 (enExample) |
| PT (1) | PT1181024E (enExample) |
| RU (1) | RU2248800C2 (enExample) |
| WO (1) | WO2000069444A1 (enExample) |
| ZA (1) | ZA200109331B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1344781A1 (en) * | 2002-03-12 | 2003-09-17 | Laboratori Derivati Organici S.P.A. | Process for the depolymerization of glycosaminoglycanes and products obtained therefrom |
| ITMI20031023A1 (it) * | 2003-05-21 | 2004-11-22 | Umberto Cornelli | Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali. |
| EP1524276A1 (en) * | 2003-10-16 | 2005-04-20 | Laboratori Derivati Organici S.P.A. | Multistep process for the physical depolymerization of heparin and products obtained therefrom |
| US7939512B2 (en) | 2004-10-13 | 2011-05-10 | Laboratori Derivati Organici Spa | Multistep process for the physical depolymerization of heparin and products obtained therefrom |
| DE602006016990D1 (de) | 2005-12-22 | 2010-10-28 | Bellus Health Int Ltd | Behandlung von diabetischer nephropathie |
| WO2009007224A1 (en) * | 2007-07-10 | 2009-01-15 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Low molecular weight heparin derivatives having neuroprotective activity |
| US8896239B2 (en) | 2008-05-22 | 2014-11-25 | Vladimir Yegorovich Balakin | Charged particle beam injection method and apparatus used in conjunction with a charged particle cancer therapy system |
| CN102119586B (zh) | 2008-05-22 | 2015-09-02 | 弗拉迪米尔·叶戈罗维奇·巴拉金 | 多场带电粒子癌症治疗方法和装置 |
| JP5450602B2 (ja) | 2008-05-22 | 2014-03-26 | エゴロヴィチ バラキン、ウラジミール | シンクロトロンによって加速された荷電粒子を用いて腫瘍を治療する腫瘍治療装置 |
| EP2283713B1 (en) | 2008-05-22 | 2018-03-28 | Vladimir Yegorovich Balakin | Multi-axis charged particle cancer therapy apparatus |
| US8841866B2 (en) | 2008-05-22 | 2014-09-23 | Vladimir Yegorovich Balakin | Charged particle beam extraction method and apparatus used in conjunction with a charged particle cancer therapy system |
| SG173879A1 (en) | 2009-03-04 | 2011-10-28 | Protom Aozt | Multi-field charged particle cancer therapy method and apparatus |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| ES2675993T3 (es) * | 2011-10-14 | 2018-07-16 | Centre National De La Recherche Scientifique | Procedimiento de diagnóstico, pronóstico o tratamiento de enfermedades neurodegenerativas |
| CN112426434A (zh) * | 2020-11-04 | 2021-03-02 | 山东大学 | 硫酸乙酰肝素在防治阿尔兹海默症中的应用 |
| CN114478816A (zh) * | 2022-02-11 | 2022-05-13 | 上海兴糖生物技术有限公司 | 一种白玉蜗牛多糖及其制备方法和用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4351938A (en) * | 1980-05-19 | 1982-09-28 | Riker Laboratories, Inc. | Anticoagulant substance |
| US4847338A (en) * | 1985-03-28 | 1989-07-11 | University Of Iowa Research Foundation | Low molecular weight heparin fragments as inhibitors of complement activation |
| EP0243974B1 (en) * | 1986-05-01 | 1994-03-02 | Toppan Printing Co., Ltd. | Scanner set-up simulation apparatus |
| IT1213384B (it) * | 1986-11-24 | 1989-12-20 | Lab Derivati Organici Mediolan | Processo per la preparazione controllata di gilcosaminoglicani a basso peso molecolare. |
| IT1205042B (it) * | 1987-05-28 | 1989-03-10 | Crinos Industria Farmaco | Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer |
| EP0337327A1 (en) * | 1988-04-09 | 1989-10-18 | Bioiberica, S.A. | Process for the preparation of new oligosaccharide fractions by controlled chemical depolimerization of heparin |
| IT1240615B (it) * | 1990-04-03 | 1993-12-17 | Mediolanum Farmaceutici Spa | Impiego del dermatan solfato nella prevenzione e terapia dell'invecchiamento cerebrale e degli stati di deficit funzionale del sistema nervoso centrale |
| IL100555A (en) * | 1991-02-07 | 2000-08-31 | Hoechst Marion Roussel Inc | N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them |
| SK279285B6 (sk) * | 1991-05-02 | 1998-09-09 | Daiichi Pharmaceutical Co. | Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin |
| RU2106864C1 (ru) * | 1995-10-23 | 1998-03-20 | Николай Серафимович Зефиров | Средство для лечения болезни альцгеймера |
-
1999
- 1999-05-14 IT IT1999MI001066A patent/IT1312107B1/it active
-
2000
- 2000-05-12 AU AU44052/00A patent/AU764743C/en not_active Ceased
- 2000-05-12 EP EP00925281A patent/EP1181024B1/en not_active Expired - Lifetime
- 2000-05-12 CZ CZ20014092A patent/CZ20014092A3/cs unknown
- 2000-05-12 IL IL14645800A patent/IL146458A0/xx not_active IP Right Cessation
- 2000-05-12 DK DK00925281T patent/DK1181024T3/da active
- 2000-05-12 AT AT00925281T patent/ATE288761T1/de not_active IP Right Cessation
- 2000-05-12 ES ES00925281T patent/ES2237425T3/es not_active Expired - Lifetime
- 2000-05-12 HK HK02101550.8A patent/HK1039903B/en not_active IP Right Cessation
- 2000-05-12 HU HU0201100A patent/HUP0201100A3/hu unknown
- 2000-05-12 RU RU2001130882/14A patent/RU2248800C2/ru not_active IP Right Cessation
- 2000-05-12 DE DE60018061T patent/DE60018061T2/de not_active Expired - Fee Related
- 2000-05-12 CN CNB00807562XA patent/CN1178667C/zh not_active Expired - Fee Related
- 2000-05-12 PT PT00925281T patent/PT1181024E/pt unknown
- 2000-05-12 US US10/048,542 patent/US6979680B1/en not_active Expired - Fee Related
- 2000-05-12 JP JP2000617903A patent/JP2002544233A/ja active Pending
- 2000-05-12 PL PL352070A patent/PL198016B1/pl not_active IP Right Cessation
- 2000-05-12 KR KR1020017014505A patent/KR100711142B1/ko not_active Expired - Fee Related
- 2000-05-12 CA CA002373975A patent/CA2373975A1/en not_active Abandoned
- 2000-05-12 WO PCT/EP2000/004311 patent/WO2000069444A1/en not_active Ceased
-
2001
- 2001-11-13 NO NO20015544A patent/NO328902B1/no not_active IP Right Cessation
- 2001-11-13 ZA ZA200109331A patent/ZA200109331B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002544233A5 (enExample) | ||
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| CA2093806A1 (en) | Method of treating or preventing type 1 diabetes by oral administration of insulin | |
| RU2002127804A (ru) | Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения | |
| ES2089027T3 (es) | Forma de dosificacion transmucosica. | |
| EP0377272A3 (en) | Use of nalmefene or naltrexone in the manufacture of a medicament for the treatment of inflammation in an arthritic disease or associated inflammatory diseases | |
| NZ569331A (en) | COP 1 for treatment of inflammatory bowel diseases | |
| JP2002523370A5 (enExample) | ||
| JP2002528502A5 (enExample) | ||
| RU2001130882A (ru) | Гликозаминогликаны, пригодные для лечения старческого слабоумия | |
| EP0375628A3 (en) | Use of acetyl l-carnitine in the therapeutic treatment of cataract, and pharmaceutical compositions useful in such treatment | |
| WO2004017913A3 (en) | Arginine silicate inositol complex and use thereof | |
| AU647463B2 (en) | A method and a pharmaceutical preparation for treating pain | |
| CA2180178A1 (en) | Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis | |
| JP2003514025A5 (enExample) | ||
| JP2002530353A5 (enExample) | ||
| WO2004032858A3 (en) | Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics | |
| WO2003015690B1 (en) | Method for treating primary insomnia | |
| CA2450915A1 (en) | Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure | |
| RU2002129298A (ru) | Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера | |
| CA2076149A1 (en) | Potentiation of antitussive effect of dextromethorphan | |
| JP2005529152A5 (enExample) | ||
| HUP0201629A2 (hu) | Eletriptánt és ciklodextrinszármazékot tartalmazó gyógyászati komplex, ezt tartalmazó gyógyszerkészítmény, eljárás az előállítására és alkalmazása | |
| WO2006131833A3 (en) | New hybrid oligomers. their preparation process and pharmaceutical compositions containing them | |
| US5081129A (en) | Method of treatment of anemia with seratonin antagonists |